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The phenotypic spectrum of WWOX-related disorders: 20
additional cases of WOREE syndrome and review of the
literature
A full list of authors and affiliations appears at the end of the paper.
Purpose: Germline WWOX pathogenic variants have been
associated with disorder of sex differentiation (DSD), spinocer-
ebellar ataxia (SCA), and WWOX-related epileptic encephalopathy
(WOREE syndrome). We review clinical and molecular data on
WWOX-related disorders, further describing WOREE syndrome
and phenotype/genotype correlations.
Methods: We report clinical and molecular findings in 20
additional patients from 18 unrelated families with WOREE
syndrome and biallelic pathogenic variants in the WWOX gene.
Different molecular screening approaches were used (quantitative
polymerase chain reaction/multiplex ligation-dependent probe
amplification [qPCR/MLPA], array comparative genomic hybridi-
zation [array-CGH], Sanger sequencing, epilepsy gene panel, exome
sequencing), genome sequencing.
Results: Two copy-number variations (CNVs) or two single-
nucleotide variations (SNVs) were found respectively in four and
nine families, with compound heterozygosity for one SNV and
one CNV in five families. Eight novel missense pathogenic
variants have been described. By aggregating our patients with
all cases reported in the literature, 37 patients from 27 families
with WOREE syndrome are known. This review suggests
WOREE syndrome is a very severe epileptic encephalopathy
characterized by absence of language development and acquisi-
tion of walking, early-onset drug-resistant seizures, ophthalmo-
logical involvement, and a high likelihood of premature death.
The most severe clinical presentation seems to be associated with
null genotypes.
Conclusion: Germline pathogenic variants in WWOX are clearly
associated with a severe early-onset epileptic encephalopathy. We
report here the largest cohort of individuals with WOREE
syndrome.
Genetics in Medicine (2018) https://doi.org/10.1038/s41436-018-
0339-3
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INTRODUCTION
WWOX (WW domain-containing oxidoreductase) is located on
chromosome 16q23.1-q23.2 and was first implicated in cancer.
It crosses the second most common fragile site (FRA16D) in the
human genome. Somatic sequence variants in WWOX were
found in many types of neoplasia and WWOX is recognized as
an important tumor suppressor gene.1 More recently, germline
pathogenic variants in WWOX were implicated in constitu-
tional diseases and three different WWOX-related phenotypes
were described: disorder of sex differentiation (DSD), spinocer-
ebellar ataxia (SCA), and epileptic encephalopathy. A hetero-
zygous in-frame deletion of exons 6 to 8 in WWOX was first
associated with DSD in a young male patient.2 Comprehensive
genetic analyses by array comparative genomic hybridization
(array-CGH) or exome sequencing (ES) identified WWOX
pathogenic variants in autosomal recessive neurological dis-
eases. Homozygous missense pathogenic variants in WWOX
were found in two consanguineous families with spinocerebellar
ataxia type 12 (SCAR12) associated with epilepsy and
intellectual disabilty.3 Biallelic pathogenic variants in WWOX
were subsequently implicated in a form of autosomal recessive
infantile epileptic encephalopathy called WWOX-related epi-
leptic encephalopathy (WOREE) syndrome.4–9
We report here 20 additional patients with biallelic
pathogenic variants in the WWOX gene associated with
severe early-onset encephalopathy. After a literature review,
we define the main clinical features of the WWOX-related
disorders and discuss genotype–phenotype correlations.
MATERIALS AND METHODS
Patients
Individuals with WWOX biallelic pathogenic variants and
epileptic encephalopathy were collected from France, England,
Italy, the Netherlands, Romania, and the United States. Copy-
Corrected: Author Correction
Submitted 10 July 2018; accepted: 3 October 2018
Published online: 25 October 2018
Correspondence: Usha Kini (usha.kini@ouh.nhs.uk)
These authors contributed equally: Juliette Piard and Lara Hawkes.
ARTICLE
GENETICS in MEDICINE | Volume 0 | Number 0 | Month 1
number variations (CNVs) were identified by multiplex
ligation-dependent probe amplification (MLPA) (4 patients)
or array-CGH (4 patients). Single-nucleotide variations (SNVs)
were identified by targeted WWOX Sanger sequencing
(2 patients), epilepsy gene panel (2 patients), exome sequencing
(ES) 9 patients), or by GS (genome sequencing), 1 patient. All
variations identified by epilepsy gene panel, ES, and array-CGH
were confirmed by Sanger sequencing and MLPA/quantitative
polymerase chain reaction (qPCR) respectively. In all cases,
parents were tested by targeted Sanger sequencing, MLPA, or
qPCR to confirm that the variations found in the proband were
in trans. Upon identification of two pathogenic or likely
pathogenic variants in WWOX, the referring clinicians were
contacted and the clinical data collected (Supplemental Table 1).
Written informed consent was obtained for genetic testing
and use of photographs (if applicable).
Methods
Array-CGH
CNVs were detected using the Human Genome Microarray
CGH 180 K, from Agilent® according to the manufacturer’s
protocol (Agilent Technologies, Santa Clara, CA) and
different Illumina single-nucleotide polymorphism (SNP)
arrays (Human Omni 1, Omni 2.5, and Omni 5 BeadChip
arrays). Data of the CGH were processed with Feature
Extraction (v. 12.0.1.1) software and the results were analyzed
with CytoGenomics (v. 3.02.11) software (Agilent®). Mapping
data were analyzed on the human genome sequence using
Ensembl (Hg19). (ref. 10). CNVs were assessed in BENCH Lab
CNV (v5.1.1). CNV changes identified by microarray in the
affected child analysis were confirmed by quantitative qPCR
in the proband and both parents. Real-time PCR reactions
were performed in the LightCycler 480 system (Roche) using
the SYBR Green I Master Kit (Eurogentec, Seraing, Belgium)
with 2 mL of complementary DNA (cDNA) and 200 nM of
each primer. Each reaction was performed in triplicate.11
MLPA
Large rearrangement screening of the WWOX gene or
validation of CNVs involving all or part of the WWOX locus
identified by array-CGH was performed by MLPA (MRC-
Holland). We designed synthetic probes for all nine exons of
theWWOX gene not covered by any probe mix available from
MRC-Holland at the time of this study. DNA sequences of
MLPA probes used in this study are available upon request.
ABIF files were analyzed by using the Coffalyser.Net, a free
MLPA analysis software developed by MRC-Holland.
Epilepsy gene panel
For patients 6 and 7, a gene panel comprising 90 genes
involved in epilepsy was performed. The genes were selected
based on previous literature and OMIM databases. A library
of all coding exons and intron–exon boundaries was prepared
using a SeqCap EZ Library (Roche-NimbleGen, USA)
following the manufacturer’s instructions. Gene panel
sequencing was performed on a MiSeq (Illumina Inc., CA).
Sequence alignment was performed by Genodiag (Paris,
France) with Burrows–Wheeler Aligner (BWA) 0.7.12,
picard-tools-1.121, GATK-3.5 (Indel realignment, base recali-
bration). Then, the variant calling and annotations were made
with Genome Analysis Toolkit (GATK)-3.5 (HaplotypeCaller)
and SNPEff-4.2 with additional information from gnomAD,
ClinVar, and the Human Gene Mutation Database (HGMD).
ES
Solo or trio-based ES approaches were performed. One
microgram of genomic DNA extracted from blood leukocytes
was used for targeted exon enrichment with the SureSelect
Human All Exon V4 kit (Agilent) on a HiSeq 2000 instrument
(Illumina) according to the manufacturer’s recommendations
for paired-end 76-bp reads. Raw data were processed as
previously described.12 AM files were aligned to a human
genome reference sequence (GRCh37/hg19) using BWA
v0.6.7 and potential duplicate paired-end reads were removed
by Picard 1.109. Indel realignment and base quality score
recalibration were conducted with GATK v3.3-0. Variations
with a quality score >30 and alignment quality score >20 were
annotated with SeattleSeq SNP Annotation.13 Rare variations
present at a frequency above 1% in dbSNP 138 and the
National Heart, Lung, and Blood Institute (NHLBI) GO
Exome Sequencing Project or present from local exomes of
unaffected individuals were excluded. Variation prioritization
focused on de novo heterozygous, compound heterozygous,
or hemizygous variants affecting the coding sequence
(missense, nonsense, and splice-site variants and coding
indels). Candidate variants were then inspected with the
Integrative Genomics Viewer.14 Candidate variants were
confirmed by means of Sanger sequencing.
GS
A Solo GS approach was performed. One microgram of
genomic DNA was prepared using an Illumina TruSeq DNA
PCR-free library preparation kit and then sequenced on a
HiSeq 2000 instrument (Illumina) according to the manu-
facturer’s recommendations. Sequence alignment and variant
calling were performed within BaseSpace (basespace.illumina.
com) using ISAAC Whole Genome Sequencing v3. Sequence
reads were aligned to the human genome reference sequence
(GRCh37/hg19). Structural variant analysis was performed
using BreakDancer15 and copy number variation analysis was
undertaken using BIC-seq software.16 Rare variations present
at a frequency above 1% in dbSNP 138 and the NHLBI GO
Exome Sequencing Project were excluded. Variants were
restricted to a targeted epileptic encephalopathy-related gene
panel, which included WWOX (a list of targeted genes is
available on request). Candidate variants were confirmed by
Sanger sequencing and testing parental samples confirmed the
WWOX variants were on separate alleles.
Sanger sequencing
We screened for SNVs the entire coding sequence plus
exon–intron boundaries by direct sequencing of PCR
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products. Exons 1 to 9 of the WWOX gene were PCR
amplified (primer sequences available upon request).
Primers were modified by the addition of either M13F
(5’-tgtaaaacgacggccagt-3’) or M13R (5’-caggaaacagtcatgacc)
sequences at their 5’ end. The coding sequence was
screened by direct DNA sequencing with M13F and
M13R primers as described earlier.17 Sequences were
automatically analyzed with the Seqscape 2.5 software
(Applied Biosystems).
Description of sequence variants
Sequence variants in the WWOX gene are numbered starting
from the first base of the ATG codon, numbering based on
the 9 coding exons reference sequence NM_016373.2. For
CNVs detected by array-CGH, the distances from the 16p
telomere are derived from the National Center for Biotech-
nology Information (NCBI) Genome Browser (build 37)
(ref. 18). Description of the sequence (Human Genome
Variation Society)19 was done with the assistance of Mutalyser
2.0.26 with the Name Checker DNA tool.
RESULTS
We report clinical and molecular findings in 20 patients with
severe early-onset epileptic encephalopathy and biallelic
pathogenic variants affecting the WWOX locus.
Molecular findings
Biallelic genetic anomalies were compound heterozygous in
14 index patients and homozygous in the others with
genetically related parents (Supplemental Table 1). The
WWOX genotypes were composed of two CNVs or two
SNVs in 4 and 9 families respectively. In 5 families, a
compound heterozygous status with one SNV and one CNV
has been revealed through a combination of two molecular
screening approaches. Two patients (P2 and P4) were found
to carry two different CNVs, each affecting a single exon.
After array-CGH, P4 was initially described as heterozygous
for a deletion affecting exons 5 to 7 of WWOX. Because the
clinical phenotype in P4 is very reminiscent of WOREE
syndrome, we decided to perform a complementary targeted
WWOX screening. The correct compound heterozygous
status with two single exon deletions in P4 was only
determined after MLPA analysis. Both CNVs in P2 were
characterized by a first-line MLPA analysis.
We identified eight new missense variations inWWOX, two
of which were not located in a known functional domain: p.
(Glu17Lys) and p.(Thr358Ile) (Supplemental Table 2). Four
missense variations were recurrent: p.(Gln230Pro) was found
in four families, p.(Gly137Glu) in three families, and p.
(Ser318Leu) and p.(Pro47Arg) in two families. All missense
variations identified in this study but one (p.[Ser318Leu])
were classified as probably damaging by the PolyPhen-2
prediction tool. None of the eight missense variants reported
for the first time in this study are present in a homozygous
state in gnomAD20 (Supplemental Table 2).
Demographic data
Twenty patients belonging to 18 unrelated families were
identified with biallelic WWOX pathogenic variants. Eight
were male (40%) and 12 were female (60%). The median age
at last follow-up was 52 months (min: 3 months; max: 17
years). The majority of patients were unrelated except for two
pairs of siblings (P13 and P14; P15 and P16). Among the 18
families, 5 were consanguineous (28%).
Prenatal and neonatal abnormalities
Prenatal features were observed in 5 of 20 patients (25%).
Anomalies described included decreased fetal movement for
three cases (with talipes in one), macrosomia, and unilateral
clubfoot. In the neonatal period, hands and feet anomalies
(not seen by ultrasound follow-up) were reported in three
more patients (clenched fists, flexed hands, and clubfeet).
Other anomalies were feeding difficulties in two patients,
hypotonia, lip smacking, and jaundice (each in one case). One
patient required resuscitation.
General clinical data
Mean height was –1,1 SD (standard deviation) with only one
patient under 3 SD (1/17; 6%). Mean occipitofrontal circum-
ference (OFC) was –1,4 SD and 4 of 20 (20%) patients had
microcephaly (defined by OFC ≤ –3 SD). Facial dysmorphism
was reported in 12 of 20 (60%) individuals. Scoliosis or
kyphosis was present in 13 of 20 (65%) patients. Feeding
difficulties were observed in most of the patients and 13/19
(70%) required a feeding tube. Respiratory problems includ-
ing respiratory failure, asthma, recurrent infections, irregular
breathing pattern, or aspiration pneumonia were reported in 8
of 20 (40%) patients. Hearing loss and cleft palate were
each reported in a single patient. Premature death (i.e.,
before 3 years) occurred in 8 of 20 patients (40%) with mean
age at death of 40 months (range: 6 months to 8 years
11 months).
Neurodevelopmental data
All patients had profound developmental delay and were not
able to either sit or walk. They had no language. Poor
spontaneous movements were reported in 17 of 19 (89%).
Hypotonia (mostly axial) was observed in 15 of 20 (75%)
patients and hypertonia (mostly distal) in 15 of 18 (83%).
Various movement disorders were present in 6 of 18 (33%)
cases.
All patients developed seizures (20/20; 100%). Mean age of
onset was 1.6 months ranging from day 1 to 7 months. Drug
resistance was reported in 19 of 20 (95%) patients. Where
frequency of seizures was reported, all patients had daily
seizures (up to >30 per day). Seizures were of varying types
and were either focal or generalized. Few patients had febrile
seizures (2/17; 12%) and 4 of 17 (23%) had status epilepticus.
A defined epileptic syndrome was documented in 7 of 19
(37%) patients. Five developed West syndrome (5/19; 26%)
and two developed Lennox–Gastaut syndrome (2/19; 11%).
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Brain magnetic resonance image (MRI) was abnormal
in 80% (16/20) of our patients; corpus callosum hypoplasia
(15/20; 75%) and progressive cerebral atrophy (11/20; 55%)
being the most prominent anomalies. White matter hyper-
signal (2/20) and delayed myelination (1/20) were occasionally
reported.
Ophthalmological features
Of 20 patients, 16 (75%) had no eye contact or poor eye
contact. Fundus oculi was altered in 9/19 patients (47%) and
electrodiagnostic tests were abnormal in 5/11 (45%) patients.
Retinal dystrophy was diagnosed in 2/19 (10%) patients and
optic nerve anomalies in 10/19 (53%).
DISCUSSION
WWOX is located on the long arm of chromosome 16 in a
known fragile site. It is composed of nine exons and is >1Mb in
size.1 The canonical transcript (ENST00000566780.5,
NM_016373.3) encodes a 414–amino acid (aa) ubiquitous
protein highly expressed in the prostate, gonads, breast, lung,
endocrine tissues, and brain.21,22 Alternative splicing ofWWOX
during precursor messenger RNA (pre-mRNA) processing
generates eight transcripts that have been observed only in
cancers; whether every aberrant WWOX mRNA is translated
into protein is unknown.23 The WW domain-containing
oxidoreductase is the only protein that couples two distinct
domains with high homologies with both the WW domain
family and SRD superfamily. WWOX harbors two WW
domains at the amino terminus, a nuclear localization signal
(NLS) motif and a C-terminal short-chain dehydrogenase
reductase (SDR) domain (Fig. 1b). A mitochondrial targeting
sequence (MTS) motif has also been mapped within the SDR
domain between aa 209 and aa 273 (ref. 24). WWOX also
contains both a coenzyme, NAD(H) or NADP(h) binding site
(GANSGIG, aa 131–137), and a potential substrate binding site
(YNRSK, aa 293–297) (ref. 1). The C-terminal domain of
WWOX (aa 125–414) is similar to a MAPT interaction region
(http://www.uniprot.org/uniprot/Q9NZC7).
WWOX is tolerant to missense variations with a missense
constraint metric Z= –3.19 (Exome Aggregation Consor-
tium).20 Many heterozygous CNVs affecting all or part of this
gene are observed in healthy control samples (Database of
Genomic Variants).25 The high number of pathogenic/
probably pathogenic variations in public databases is not
surprising considering an autosomal recessive mode of
inheritance for WWOX-related encephalopathy.
WWOX is expressed in mouse developing nervous system
including cerebral cortex and cerebellum from in utero stages
to adulthood.26 Animal models demonstrated epilepsy and
ataxia caused by WWOX loss,3,27 suggesting a neurodegen-
erative process. In a detailed review of the literature, Aldaz
and collaborators clearly demonstrated that WWOX is at the
crossroads of cancer, metabolic syndrome, and
encephalopathy.28
Clinical and molecular data for all patients from the literature
with either SCAR12 or WOREE phenotypes are described in
Supplemental Table 3 (refs. 3–8,29,30). Two additional patients,
sisters from a consanguineous Arab family with a WWOX
homozygous variant (c.1228G>T; p.Gly410Cys), were also
reported by Alkhateeb et al. in 2016 (ref. 9), but there is doubt
as to the pathogenicity of the variant identified in these cases.
Both presented with delayed speech and one had epilepsy
from 2 years of age. The clinical presentation in this family is
very mild as compared with the WOREE syndrome observed
in patients with biallelic germline pathogenic variants in
WWOX. This glycine to cysteine change at position 410
affects an amino acid at the very end of the carboxyl terminus
side of the protein. Additionally this amino acid change is
present in homozygous form in two individuals in the
gnomAD data set. Although in silico predictions are in favor
of the pathogenicity of this missense pathogenic variant
(possibly damaging by PolyPhen-2), its causal role is
questionable in this family. We have therefore decided to
exclude these patients from our literature review.
We report here on the largest cohort of individuals with a
WOREE phenotype consisting of 20 additional patients with
biallelic pathogenic variants in WWOX inherited from
healthy parents (Supplemental Table 1). Molecular diagnoses
were obtained by a combination of different techniques
(array-CGH, qPCR/MLPA, targeted Sanger sequencing, ES
and WGS). By aggregating our patients with all cases reported
so far in the literature, 37 patients from 27 families with a
WOREE syndrome and biallelic WWOX pathogenic variants
are known. A total of 29 different pathogenic/likely
pathogenic alleles (10 CNVs and 19 SNVs) have been
identified (Fig. 1a, b). Introns 5 and 8 of the WWOX gene
are very large with a size of 220 and 780 Kb respectively. They
cover 90% of the WWOX genomic sequence and contain
translocation breakpoints for multiple myeloma,28 in accor-
dance with the fact that large intronic regions are often
recombinogenic and prone to chromosomal breakpoints.
Accordingly, duplication (one allele) and deletion (five alleles)
encompassing exons 6 to 8 are the most frequent pathogenic
CNVs observed in patients with WWOX-related disorders
(Supplemental Tables 1 and 3). All patients from consangui-
neous families (10/27; 37%) were found to be homozygous for
the same deleterious allele, a common occurrence in
autosomal recessive disorders with a low prevalence. The
high proportion of families with a genotype comprising one
or two pathogenic CNVs (14/27; 52%) highlights the need for
a quantitative approach for screening the WWOX locus in
patients with severe central nervous system disorders. In
patients heterozygous for a CNV affecting several exons, it is
important to search for (1) a possible compound hetero-
zygous genotype for two small CNVs and the need for a
second quantitative analysis by MLPA or qPCR in both
parents and (2) a SNV on the second allele by targeted Sanger
sequencing. In the same way, when ES or targeted gene panel
sequencing is performed as a first-line investigation, the
search for CNVs is essential in this large gene prone to
deletions and duplications, involving all or part of its coding
sequences.
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In this study we report eight new missense pathogenic
variants (Supplemental Table 2). Among exome and targeted
gene panel high-throughput sequencing results, WWOX
missense variants are numerous. Their pathogenicity is
difficult to establish because WWOX has numerous functions
and protein partners. We followed American College of
Medical Genetics and Genomics (ACMG) guidelines31 for
interpreting and annotating missense variations in WWOX
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Fig. 1 WWOX germline pathogenic variants identified in patients with constitutional WWOX-related disorders (SCAR12, WOREE syndrome,
and DSD). a Copy-number variations (n= 12). DSD disorder of sex development, IF in frame, OOF out of frame, WOREE WWOX-related epileptic
encephalopathy. b Single-nucleotide variations (n= 23). MTS mitochondrial targeting sequence, NLS nuclear localization signal, SRD short-chain dehy-
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data to classify them as pathogenic, likely pathogenic, variants
of unknown significance (VUS), likely benign, or benign. To
aid our variant interpretation process, we used an openly
available online tool (http://www.medschool.umaryland.edu/
Genetic_Variant_Interpretation_Tool1.html/) to efficiently
classify variants based on the evidence categories outlined
by ACMG guidelines.31 Four aa changes (p.[Gly137Glu], p.
[His150Pro], p.[Gln230Pro], p.[Ser318Leu]) are associated in
trans with null variants in a gene where loss of function is a
known disease mechanism. All missense variants identified in
individuals with WWOX-related encephalopathy (11 aa
changes in 12 families, Supplemental Table 2) are predicted
to be disease-causing by a combination of web-based
softwares. More importantly, none are present in a homo-
zygous state in gnomAD.20 All missense variants are classified
as pathogenic or likely pathogenic according to the ACMG
recommendations. One patient (P19) is a carrier of three
different missense pathogenic variants: p.[Lys200Glu;
Thr358Ile];[Gln230Pro] (Supplemental Table 1). The p.
(Lys200Glu) and p.(Thr358Ile) are located in cis; both amino
acid changes are predicted to be likely pathogenic although
the threonine at position 358 is not located in a known
functional domain. It is not possible to determine whether
one or both of these variants are the disease-causing missense
variant in P19. In most cases reported here and published in
the medical literature, WWOX sequence variations are
described at the basic DNA level. All missense pathogenic
variants but one (P3; p.[Ser318Leu]) are interpreted based on
in silico studies without experimental evidence (no RNA or
protein sequence analyzed). In P3, total RNA analysis by
Sanger sequencing of reverse transcription PCR (RT-PCR)
products failed to detect any splicing anomaly in leukocytes.
RNA studies were not performed for other patients because
appropriate blood samples were not available at the time of
the molecular diagnosis. Exonic SNVs could affect physiolo-
gical acceptor/donor splice sites, but also exonic splicing
enhancer (ESE) and exonic splicing silencer (ESS). Moreover,
the activation of cryptic splice sites by SNVs is a well-
understood pathological mechanism in many genetic dis-
orders; a good example of this is Hutchinson–Gilford progeria
syndrome.32 Missense variants could also impact on mRNA
stability.33 Up to 10% of known disease-associated missense
variants, but only 3% of common SNPs, alter pre-mRNA
splicing.33 It is likely that a fraction of predicted missense
variants identified in patients with WWOX-related encepha-
lopathy results in loss of expression due to abnormal splicing.
This is all the more probable for a gene with pathogenic loss-
of-function alleles. For missense pathogenic variants in the
SRD domain, the absence of identified substrates makes it
difficult to evaluate their impact on WWOX’s catalytic
activity. Characterization of knock-in animal models such as
zebrafish would give clues about the pathogenicity of WWOX
missense variants.
In one patient not included in this study, a molecular
diagnosis of WWOX-related encephalopathy was initially
suspected in front of a biallelic genotype consisting of two
SNVs in trans: a nonsense (ENST00000566780.5:p.Gln72*)
and a missense variant (ENST00000402655:c.600T>A, p.
Ser200Arg). The aa change at position 200 only affects a
non-RefSeq WWOX protein of 311 residues. So far, all
pathogenic aa changes have been described according to the
canonical WWOX protein (414 aa), which results from the
translation of a 9-exon transcript (ENST00000566780.5,
isoform 1). It is unknown whether the WWOX protein
isoform composed of 311 residues is relevant for WWOX-
related disorders. Additionally, the phenotype in this patient
was mild compared with the WOREE syndrome. For these
reasons, we decided not to consider this genotype as causative
for the encephalopathy in this patient.
WWOX, cancer, and lung disease?
WWOX is a tumor suppressor gene involved in the
modulation of cancer-related pathways via protein–protein
interactions between the WW domains and various oncogenic
proteins. Loss of WWOX protein was found in multiple
neoplasias.23 Osteosarcomas and lung carcinomas are
observed in Wwox-/- mice22 and tumorigenesis is one of
the consequences of a Wwox hypomorphic genotype.34 A
functional loss of copy CNV (67048) in WWOX was
significantly associated with an increased cancer risk in
Chinese populations.35–37 More recently, loss of WWOX
expression in mice lung was shown to cause neutrophilic
inflammation.38 Surprisingly, increase in cancer cases was
never reported in either patients with biallelic WWOX
germline pathogenic variants or their heterozygous parents.
The severity of WOREE syndrome with a high frequency of
premature death in the first years of life could explain the
absence of any cancers. This is not a convincing explanation
for patients heterozygous for aWWOX null allele. Ablation of
Wwox is not tumorigenic in all knockout animal models; this
putative tumor suppressor gene is more likely to be of
relevance in tumor progression rather than initiation during
oncogenesis. This study confirms that germline WWOX
alterations are not driver pathogenic variants important for
cancer initiation and/or progression.
WWOX and DSD
WWOX is highly expressed in hormonally regulated tissues
such as the pituitary, testis, and ovary, and is presumed to
play a role in gonadotropin or sex-steroid biosynthesis.1,39
The SRD enzymatic domain in WWOX is thought to have a
role in steroid metabolism with as yet unidentified substrates.
These observations and the description of two different
WWOX knockout mouse models with gonadal abnormal-
ities34,39 clearly support a role for WWOX in gonad
development.
The first germline rearrangement ofWWOX in humans was
associated with a 46, XY DSD.2 The patient had bilateral
undifferentiated gonadal tissue and immature testes. He was
heterozygous for a deletion of exons 6 to 8 inherited from his
mother who had a personal history of late menarche. This
CNV is predicted to result in an in-frame deletion, causing
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shortened product with the SRD domain largely missing.
More recently, three heterozygous VUS in the WWOX gene
were identified by ES in patients with DSD (Fig. 1) (ref. 40).
To our knowledge, DSD has not been reported in hetero-
zygous parents of patients with WOREE syndrome and we
believe that the implication of heterozygous SNVs/CNVs in
the molecular etiology of DSD is questionable. Testicular
atrophy, reduced fertility, gonadal abnormalities, Leydig cell
dysfunction, and impaired mammary development are part of
the phenotypes observed in several animal models of WWOX
ablation.28 To our knowledge, DSD is not reported in
heterozygous knockout animal models. However, a possibility
remains that a milder phenotype could be identified after
careful evaluation of sex development and gonadal function in
patients heterozygous for a WWOX pathogenic variant.
SCAR12 phenotype
In 2014, homozygous missense pathogenic variants inWWOX
were identified by ES in six patients from two consanguineous
families with autosomal recessive spinocerebellar ataxia
(SCAR12). So far, this association was not confirmed in
additional families. Affected patients presented with
childhood-onset cerebellar ataxia, generalized tonic–clonic
epilepsy, intellectual disability, and prominent spasticity.3
Compared with patients with WOREE syndrome, patients
with SCAR12 phenotype have a less severe developmental
delay: all were able to walk (4/4; 100%), 3 of 4 were able to
speak, and no premature death was reported. When
performed, brain MRI showed mild cerebellar hypoplasia (2/
2; 100%) in affected patients, a feature not observed in our
cohort. Although epilepsy was a constant feature in SCAR12
patients, seizures were more often responsive to antiepileptic
drugs (2/4; 50%). Eye involvement was also present with
nystagmus reported in four patients. This form of WWOX-
related autosomal recessive cerebellar ataxia seems to be a rare
genetic condition. The severity of the WOREE phenotype and
premature death in a proportion of patients might hide
balance problems related to cerebellar dysfunction. Additional
cases of WWOX-related cerebellar ataxia are needed to
confirm its implication in this neurological disorder.
WOREE phenotype
Soon after the description of the SCAR12 phenotype, WWOX
was implicated in a recessive form of infantile epileptic
encephalopathy in 17 patients from 9 families.4–9,30 We are
more than doubling the number of cases with 20 affected
patients in 18 additional families. The phenotype of our
patients is consistent with that of previous reports. We
observed a lower rate of consanguinity in our cohort in
accordance with the higher proportion of compound hetero-
zygous genotypes described in this study. These genotypes
might have been previously missed when array-CGH or high-
throughput sequencing were performed independently. The
implementation of CNV prediction from exome sequence
data facilitates the identification of patients with WWOX
genotypes composed of both SNV and CNV.
One fetus with brain anomalies and possible intrauterine
seizures was reported in 2015 (ref. 7). Decreased fetal
movements were occasionally reported in our series (3/20)
whereas increased nuchal translucency was the most frequent
sign during pregnancy in previous reports (4/17). Hands and
feet contractures were reported in 5 patients in our cohort and
in 3 patients from the literature4–6 in the prenatal or neonatal
period. Decreased fetal movements, increased nuchal translu-
cency, and hands or feet anomalies could be antenatal signs of
the disease but are neither specific nor frequent clinical
features.
By contrast to the literature, growth retardation (6%) and
microcephaly (20%) were not prominent features in our
patients who presented with normal low mean height (–1.1
SD) and mean OFC (–1.4 SD). Dysmorphism was reported in
more than half of the patients. The most striking features were
a round face with full cheeks, a short neck, and a hypotonic
facial appearance (Fig. 2). In patients P15 and P16, at later
age, facial hypotonia was still present but the face became
more triangular. Additional medical problems were scoliosis
or kyphosis of early onset (65%), which might guide the
diagnosis, as well as feeding troubles requiring feeding tube in
70% of patients and respiratory problems (40%), as seen in
other infantile encephalopathies.
All patients had severe developmental delay. None of them
were able to sit, speak, or walk. Neurologic examination
showed axial hypotonia and distal hypertonia in most of the
patients. Dystonic movements were occasionally observed. As
reported in the literature, all patients had early-onset epilepsy
(100%) with daily seizures and drug resistance observed in
most of the cases (95%). There was no major susceptibility to
febrile seizures. West syndrome characterized by spasms and
hypsarrhythmia recorded on EEG was reported in 26% of
patients. Focal, generalized, and combined seizures were seen.
Tonic, clonic, tonic–clonic, and myoclonic seizures as well as
infantile spasms and absences were described. Thus epilepsy
was very severe, of early onset and with variable seizure
mainfestions. As previously described, visual impairment
seems to be part of the clinical spectrum of WOREE
syndrome. Most of the affected patients had no eye contact
(75%). Around half of them presented with altered fundus
oculi (47%) and/or electrodiagnostic tests (45%) suggestive of
optic atrophy and/or retinal dystrophy. Early ophthalmolo-
gical examination therefore may give diagnostic clues in
patients with early-onset seizures and developmental delay.
Brain MRI (Fig. 3) was abnormal in 80% of patients mainly
showing corpus callosum hypoplasia (75%) and cerebral
atrophy (55%). We confirmed in our cohort that premature
death is a feature of WOREE syndrome occurring in eight
patients (40%) with a mean age at death of 40 months. The
severity of epilepsy and neurological impairment may be
linked to early death in affected patients.
Main clinical signs in previously published patients with
WOREE are summarized in Supplemental Table 4. From this
review we can conclude that WOREE is a very severe epileptic
encephalopathy characterized by poor spontaneous mobility,
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absence of language development and acquisition of walking,
early-onset drug-resistant seizures, ophthalmological involve-
ment, and a high likelihood of premature death. Dysmorphic
features (round hypotonic face, full cheeks, and short neck)
and spine deformity may be early associated signs that may
support the diagnosis.
Phenotype/genotype correlations
Phenotype/genotype correlations were recently suggested for
WWOX-related neurodevelopmental disorders5,7 with a
classification of WWOX genotypes into three groups.
According to the tentative classification, patients carrying
two predicted null alleles were more likely to present with the
most severe WOREE phenotype whereas hypomorphic
genotypes with two missense variants would instead result
in spinocerebellar ataxia (SCAR12). The phenotype of
patients carrying a null allele and a missense pathogenic
variation would be intermediate.5 Our large study provides a
reappraisal of these preliminary correlations.
The most severe clinical presentation seems to be associated
with genotypes consisting of early premature stop codons
corresponding to WWOX full knockdown. These genotypes
are observed in seven patients: homozygous deletion of exon 1
to 4 in P10, homozygous stop codons p.(Arg54*) and p.
(Trp44*),4,30 homozygous deletion of the first six exons.7
Premature death before 2 years occurred in 5/7 cases and
brain anomalies were detected prenatally in one family.
Furthermore, premature death has never been described in
patients with missense pathogenic variant–only genotype
(Supplemental Tables 1 and 3). The precise characterization
of missense variants and CNVs at the protein level with
functional studies may give some clues about how genotypes
could explain different clinical presentations, especially
regarding SCAR12/WOREE phenotypes.
P2, 3y 5 m
P4, 3 m
P7, 2y 6 m
P12P11, 10 m P13, 8 y
P15, 6 y
P16, 9 y
P14, 18 m
P17, 7 m
P18, 3 w
P18, 9 m
Fig. 2 Photographs of individuals with WWOX-related epileptic encephalopathy (WOREE) syndrome. Note major axial hypotonia (P4 and P17);
hypotonic facial appearance (all patients); round face, full cheeks, and short neck (P2, P4, P7, P11, P12, P13, P14, P17, and P18).
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Fig. 3 Brain magnetic resonance image (MRI) of individuals withWWOX-related epileptic encephalopathy (WOREE) syndrome. a–j Hypoplastic
corpus callosum on sagittal planes. k–q Cerebral atrophy and enlarged subarachnoid spaces on axial planes (P4, P6, P14) and coronal planes (P3, P7, P17).
r–t Symmetric white matter hypersignal on axial T2. u–v Plagiocephaly and asymmetric lateral ventricle on axial T2 planes. w P19 sagittal T1 circular lesions
(hyposignal) of the medial part of the corpus callosum. m month, P patient, y year old.
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In conclusion, germline pathogenic variants in WWOX are
clearly associated with a severe early-onset epileptic encepha-
lopathy called WOREE syndrome and we report here on the
largest cohort of individuals with this neurological disorder.
Implication of constitutional WWOX variants in DSD and
SCA still needs replication studies.
ELECTRONIC SUPPLEMENTARY MATERIAL
The online version of this article (https://doi.org/10.1038/s41436-
018-0339-3) contains supplementary material, which is available
to authorized users.
ACKNOWLEDGEMENTS
This study was supported by the DDD Study. The Deciphering
Developmental Disorders (DDD) Study presents independent
research commissioned by the Health Innovation Challenge Fund
(grant number HICF-1009-003), a parallel funding partnership
between the Wellcome Trust and the Department of Health, and
the Wellcome Trust Sanger Institute (grant number WT098051).
The views expressed in this publication are those of the author(s)
and not necessarily those of the Wellcome Trust or the
Department of Health. The study has UK Research Ethics
Committee approval (10/H0305/83, granted by the Cambridge
South REC, and GEN/284/12 granted by the Republic of Ireland
REC). The research team acknowledges the support of the
National Institute for Health Research, through the Comprehen-
sive Clinical Research Network.
This study was supported by the NIHR Oxford Biomedical
Research Centre and the Wellcome Trust (090532/Z/09/Z). This
publication presents independent research commissioned by the
Health Innovation Challenge Fund (R6-388 / WT 100127), a
parallel funding partnership between the Wellcome Trust and the
Department of Health. The views expressed are those of the
authors and not necessarily those of the WT, NHS, the NIHR or
the Department of Health”
This work was supported by the Association “Les rêves d’Emmy.”
We gratefully acknowledge clinicians who have referred patients for
ES, GS array-CGH, or WWOX targeted molecular screening.
DISCLOSURE
The authors declare no conflicts of interest.
REFERENCES
1. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM.
WWOX, a novel WW domain-containing protein mapping to human
chromosome 16q23.3-24.1, a region frequently affected in breast
cancer. Cancer Res. 2000;60:2140–2145.
2. White S, Hewitt J, Turbitt E, et al. A multi-exon deletion within WWOX is
associated with a 46,XY disorder of sex development. Eur J Hum Genet.
2012;20:348–351.
3. Mallaret M, Synofzik M, Lee J, et al. The tumour suppressor gene WWOX
is mutated in autosomal recessive cerebellar ataxia with epilepsy and
mental retardation. Brain. 2014;137 Pt 2:411–419.
4. Abdel-Salam G, Thoenes M, Afifi HH, Korber F, Swan D, Bolz HJ. The
supposed tumor suppressor gene WWOX is mutated in an early lethal
microcephaly syndrome with epilepsy, growth retardation and retinal
degeneration. Orphanet J Rare Dis. 2014;9:1172–9-12.
5. Mignot C, Lambert L, Pasquier L, et al. WWOX-related encephalopathies:
delineation of the phenotypical spectrum and emerging genotype-
phenotype correlation. J Med Genet. 2015;52:61–70.
6. Ben-Salem S, Al-Shamsi AM, John A, Ali BR, Al-Gazali L. A novel whole
exon deletion in WWOX gene causes early epilepsy, intellectual disability
and optic atrophy. J Mol Neurosci. 2015;56:17–23.
7. Valduga M, Philippe C, Lambert L, et al. WWOX and severe autosomal
recessive epileptic encephalopathy: first case in the prenatal period. J
Hum Genet. 2015;60:267–271.
8. Tabarki B, AlHashem A, AlShahwan S, Alkuraya FS, Gedela S, Zuccoli G.
Severe CNS involvement in WWOX mutations: description of five new
cases. Am J Med Genet A. 2015;167A:3209–3213.
9. Alkhateeb AM, Aburahma SK, Habbab W, Thompson IR. Novel mutations
in WWOX, RARS2, and C10orf2 genes in consanguineous Arab families
with intellectual disability. Metab Brain Dis. 2016;31:901–907.
10. Zerbino DR, Achuthan P, Akanni W, et al. Ensembl 2018. Nucleic Acids
Res. 2018;46(D1):D754–61.
11. Bonnet C, Leheup B, Beri M, Philippe C, Gregoire MJ, Jonveaux P. Aberrant
GRIA3 transcripts with multi-exon duplications in a family with X-linked
mental retardation. Am J Med Genet A. 2009;149A:1280–1289.
12. Carmignac V, Thevenon J, Ades L, et al. In-frame mutations in exon 1 of
SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet.
2012;91:950–957.
13. SeattleSeq Annotation. 2016. http://snp.gs.washington.edu/
SeattleSeqAnnotation138/.
14. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative Genomics
Viewer. Nat Biotechnol. 2011;29:24–26.
15. Chen K, Wallis JW, McLellan MD et al. BreakDancer: an algorithm for
high-resolution mapping of genomic structural variation. Nat Methods.
2009;6:677–681.
16. Xi R, Hadjipanayis AG, Luquette LJ et al. Copy number variation detection
in whole-genome sequencing data using the Bayesian information
criterion. Proc Natl Acad Sci USA. 2011;108(46):E1128–E1136.
17. Quenard A, Yilmaz S, Fontaine H, et al. Deleterious mutations in exon 1
of MECP2 in Rett syndrome. Eur J Med Genet. 2006;49:313–322.
18. Genome Reference Consortium. 2009. https://www.ncbi.nlm.nih.gov/
grc.
19. Human Genome Variation Society. 2016. http://www.hgvs.org/
mutnomen/recs.html.
20. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding
genetic variation in 60,706 humans. Nature. 2016;536:285–291.
21. Nunez MI, Ludes-Meyers J, Aldaz CM. WWOX protein expression in
normal human tissues. J Mol Histol. 2006;37:115–125.
22. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox
reveals a tumor suppressor function. Proc Natl Acad Sci USA.
2007;104:3949–3954.
23. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. WW domain-containing
oxidoreductase: a candidate tumor suppressor. Trends Mol Med.
2007;13:12–22.
24. Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW
domain-containing oxidoreductase that enhances tumor necrosis factor
cytotoxicity. J Biol Chem. 2001;276:3361–3370.
25. MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. The Database
of Genomic Variants: a curated collection of structural variation in
the human genome. Nucleic Acids Res. 2014;42(Database issue):
D986–92.
26. Chen ST, Chuang JI, Wang JP, Tsai MS, Li H, Chang NS. Expression of
WW domain-containing oxidoreductase WOX1 in the developing murine
nervous system. Neuroscience. 2004;124:831–839.
27. Suzuki H, Katayama K, Takenaka M, Amakasu K, Saito K, Suzuki K. A
spontaneous mutation of the Wwox gene and audiogenic seizures in
rats with lethal dwarfism and epilepsy. Genes Brain Behav. 2009;8:
650–660.
28. Aldaz CM, Ferguson BW, Abba MC. WWOX at the crossroads of cancer,
metabolic syndrome related traits and CNS pathologies. Biochim Biophys
Acta. 2014;1846:188–200.
29. Gribaa M, Salih M, Anheim M, et al. A new form of childhood onset,
autosomal recessive spinocerebellar ataxia and epilepsy is localized at
16q21-q23. Brain. 2007;130 Pt 7:1921–1928.
30. Elsaadany L, El-Said M, Ali R, Kamel H, Ben-Omran T. W44X mutation in
the WWOX gene causes intractable seizures and developmental delay: a
case report. BMC Med Genet. 2016;17:53.
31. Richards S, Aziz N, Bale S, et al. Standards and guidelines for
the interpretation of sequence variants: a joint consensus
ARTICLE PIARD et al
10 Volume 0 | Number 0 | Month | GENETICS in MEDICINE
recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med.
2015;17:405–424.
32. De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in
Hutchinson-Gilford progeria. Science. 2003;300:2055.
33. Wu H, Boulling A, Cooper DN, et al. Analysis of the impact of known
SPINK1 missense variants on pre-mRNA splicing and/or mRNA stability in
a full-length gene assay. Genes (Basel). 2017;8. pii: E263. https://doi.org/
10.3390/genes8100263.
34. Ludes-Meyers JH, Kil H, Nunez MI, et al. WWOX hypomorphic mice
display a higher incidence of B-cell lymphomas and develop testicular
atrophy. Genes Chromosomes Cancer. 2007;46:1129–1136.
35. Yang L, Liu B, Huang B, et al. A functional copy number variation in the
WWOX gene is associated with lung cancer risk in Chinese. Hum Mol
Genet. 2013;22:1886–1894.
36. Yang L, Qiu F, Fang W, et al. The functional copy number variation-
67048 in WWOX contributes to increased risk of COPD in southern and
eastern Chinese. COPD. 2015;12:494–501.
37. Chen Y, Tan X, Ding Y, et al. WWOX CNV-67048 functions as a risk
factor for epithelial ovarian cancer in Chinese women by negatively
interacting with oral contraceptive use. Biomed Res Int.
2016;2016:6594039.
38. Singla S, Chen J, Sethuraman S, et al. Loss of lung WWOX expression
causes neutrophilic inflammation. Am J Physiol Lung Cell Mol Physiol.
2017;312:L903–11.
39. Aqeilan RI, Hagan JP, de Bruin A, et al. Targeted ablation of the WW
domain-containing oxidoreductase tumor suppressor leads to impaired
steroidogenesis. Endocrinology. 2009;150:1530–1535.
40. Kim JH, Kang E, Heo SH, et al. Diagnostic yield of targeted gene panel
sequencing to identify the genetic etiology of disorders of sex
development. Mol Cell Endocrinol. 2017;444:19–25.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License,which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The
images or other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and
your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/.
© The Author(s) 2018
Juliette Piard, MD, PhD1, Lara Hawkes, MBBCh2, Mathieu Milh, MD, PhD3,4, Laurent Villard, PhD3,5,
Renato Borgatti, MD6, Romina Romaniello, MD6, Melanie Fradin, MD7, Yline Capri, MD8,
Delphine Héron, MD9, Marie-Christine Nougues, MD10, Caroline Nava, MD, PhD11,
Oana Tarta Arsene, MD12, Debbie Shears, PhD2, John Taylor, PhD13, Alistair Pagnamenta, PhD14,
Jenny C Taylor, PhD14, Yoshimi Sogawa, MD15, Diana Johnson, MD16, Helen Firth, MD17,18,
Pradeep Vasudevan, FRCP19, Gabriela Jones, MBChB19, Marie-Ange Nguyen-Morel, MD20,
Tiffany Busa, MD5, Agathe Roubertie, MD, PhD21, Myrthe van den Born, MD22,
Elise Brischoux-Boucher, MD1, Michel Koenig, MD, PhD23,
Cyril Mignot, MD, PhD9, DDD Study18, Usha Kini, MD2 and Christophe Philippe, PhD24,25
1Centre de Génétique Humaine, Université de Franche-Comté, CHU Besançon, Besançon, France. 2Oxford Centre for Genomic
Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 3Aix Marseille Univ, Inserm, MMG, Marseille, France.
4Pediatric Neurology, La Timone Children’s Hospital, AP-HM, Marseille, France. 5Medical Genetics, La Timone Children’s Hospital,
AP-HM, Marseille, France. 6Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute IRCCS Eugenio Medea, Bosisio Parini,
Italy. 7Service de Génétique, CLAD Ouest, CHU Rennes, Rennes, France. 8Département de Génétique, Hôpital Robert Debré, APHP
Paris, Paris, France. 9APHP, Département de Génétique, Centre de Référence Déficiences Intellectuelles de Causes Rares, Groupe
Hospitalier Pitié Salpêtrière et GHUEP Hôpital Trousseau, Sorbonne Université, GRC “Déficience Intellectuelle et Autisme”, Paris,
France. 10Neuropédiatrie et Unité d’électrophysiologie clinique, Centre de Référence des Maladies Neuromusculaires de l’EST
parisien et DHU I2B, Hôpital d’Enfants Armand Trousseau, Paris, France. 11Département de Génétique, Sorbonne Universités,
Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, APHP, Hôpital de la Pitié Salpêtrière, Paris,
France. 12Pediatric Neurology Clinic, “Alexandru Obregia” Clinical Psychiatry Hospital, “Carol Davila” University of Medicine,
Bucharest, Romania. 13Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital,
Oxford, UK. 14NIHR Oxford Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
15Division of Pediatric Neurology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA. 16Department of Clinical
Genetics, Sheffield Children’s NHS Trust, Sheffield, United Kingdom. 17Department of Clinical Genetics, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK. 18Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
19Clinical Genetics Department, University Hospitals Leicester NHS Trust, Leicester, UK. 20Service de Neurologie pédiatrique, Hopital
Couple Enfant, CHU Grenoble Alpes, Grenoble, France. 21Département de Neuropédiatrie, Centre Hospitalier Universitaire de
Montpellier, INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, France. 22Department for Clinical Genetics,
Erasmus MC, Rotterdam, Netherlands. 23EA7402 Institut Universitaire de Recherche Clinique, and Laboratoire de Génétique
Moléculaire, CHU and Université de Montpellier, Montpellier, France. 24Laboratoire de génétique, Innovations en diagnostic
génomique des maladies rares, Plateau Technique de Biologie, CHU Dijon, Dijon, France. 25INSERM 1231, LNC UMR1231 GAD,
Burgundy University, Dijon, France
PIARD et al ARTICLE
GENETICS in MEDICINE | Volume 0 | Number 0 | Month 11
